← All organizations

Illumina, Inc.

For profitWebsite ↗

Also known as: Illumina, Inc. | Illumina Radiopharmaceuticals, LLC | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Last known activity

Nov 30, 2025

Timeline

1990s

Apr 1, 1998
Illumina, Inc.— Founded

2010s

Jan 1, 2011
Epicentre— Acquired

Drugs by trial phase (49 distinct, 36 trials)

Phase 4 (0 own, 15 via acquisition)

Phase 3 (1 own, 23 via acquisition)

Phase 2 (2 own, 4 via acquisition)

Other trials (0 own, 4 via acquisition)

Indications

Studied for

Cardiovascular Diseases

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Epicentre

Recent trials (5)

NCT06965621Lead sponsorPhase 2Nov 30, 2025
NCT07176286Lead sponsorPhase 2Nov 30, 2025
NCT06233903Lead sponsorPhase 2Jan 31, 2025
NCT04724369Lead sponsorPhase 3Sep 24, 2021
NCT04535193Lead sponsorPhase 1/Phase 2Nov 1, 2020

Details

Founded: San Diego, CA, US Apr 1, 1998
Last known activity: Nov 30, 2025